Enzychem Lifesciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 14 shareholders own 22.81% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.46%	Bridget Lifesciences Corporation	6,342,830	₩12.5b	0%	no data
4.94%	KB Securities Co.,Ltd, Asset Management Arm	4,200,056	₩8.3b	0%	49.71%
4.78%	Ki-Young Sohn	4,069,430	₩8.0b	0%	no data
2.61%	Norges Bank Investment Management	2,219,977	₩4.4b	-27.9%	no data
2.43%	The Vanguard Group, Inc.	2,065,982	₩4.1b	0%	no data
0.47%	Dimensional Fund Advisors LP	396,317	₩779.6m	89.5%	no data
0.075%	Hye-Kyung Kim	63,810	₩125.5m	0%	no data
0.03%	State Street Global Advisors, Inc.	25,629	₩50.4m	-11.6%	no data
0.015%	Enzychem Lifesciences Corporation, Employee Stock Ownership Association	12,600	₩24.8m	0%	no data
0.0092%	Tae-Hoon Kim	7,872	₩15.5m	0%	no data
0.0016%	Samsung Asset Management Company, Ltd.	1,333	₩2.6m	-85.7%	no data
0.00094%	Mirae Asset Global Investments Co., Ltd.	798	₩1.6m	-57.4%	no data
0.00043%	Hi Asset Management Co., Ltd.	366	₩719.5k	0%	no data
0.00029%	Hanwha Asset Management Co. Ltd.	247	₩485.2k	0%	no data